Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,668JPY
25 Jul 2016
Change (% chg)

¥12 (+0.69%)
Prev Close
¥1,656
Open
¥1,675
Day's High
¥1,682
Day's Low
¥1,661
Volume
6,130,500
Avg. Vol
7,960,405
52-wk High
¥2,009
52-wk Low
¥1,358

Latest Key Developments (Source: Significant Developments)

LEO Pharma to Acquire Global Dermatology Portfolio from Astellas Pharma Inc
Wednesday, 11 Nov 2015 06:02am EST 

LEO Pharma A/S and Astellas Pharma Inc:Leo pharma to acquire global dermatology portfolio from Astellas.Says deal valued at 675 mln Euros.The transaction does not include any manufacturing facilities.Assets,associated responsibilities relating to astellas' global portfolio of dermatology products will be transferred to leo pharma.J.p. morgan is acting as financial advisor to leo pharma.  Full Article

Astellas Pharma offers takeover bid for shares of Ocata Therapeutics
Monday, 9 Nov 2015 10:00pm EST 

Astellas Pharma Inc:Astellas Pharma Inc is offering a takeover bid for 100 pct stake (or no less than 50 pct stake) of Ocata Therapeutics Inc's stock, at the price of $8.50 per share, through Astellas Pharma's U.S.-based wholly owned sub-subsidiary Laurel Acquisition Inc. (Laurel).Astellas Pharma will hold 100 pct stake in Ocata Therapeutics, up from 0 pct.Total acquisition amount is about $379 mln.Say the offering period of 20 business days from not later than Nov. 25.Says the Ocata Therapeutics to merge with Laurel and Laurel to be dissolved after the transaction.  Full Article

Astellas Pharma to transfer business to MicroBiopharm Japan
Thursday, 29 Oct 2015 11:00pm EDT 

Astellas Pharma Inc:To transfer real estate, property of the Kiyosu factory and drug manufacturing business to MicroBiopharm Japan Co., Ltd. on April 1.  Full Article

Astellas Pharma Inc inititaties Phase 3 registration trial of gilteritinib
Wednesday, 28 Oct 2015 08:00am EDT 

Astellas Pharma Inc:Says dosing of the first patient in a randomized Phase 3 registration trial of gilteritinib versus salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia.Primary endpoint of the trial is overall survival.  Full Article

Astellas Pharma Inc and immunomic therapeutics announces worldwide partnership for lamp-Vax(TM) products for allergic disease
Friday, 9 Oct 2015 08:00am EDT 

Astellas Pharma Inc:Astellas Pharma and immunomic therapeutics announce worldwide partnership for lamp-Vax(TM) products for allergic disease.Immunomic therapeutics will receive upfront payment of $300 million.Says immunomic therapeutics will be entitled to receive 10% royalties of net sales of the potential products.Says impact of transaction on astellas' financial results for the fiscal year ending March 31, 2016 will be immaterial.  Full Article

Astellas Pharma enters into exclusive worldwide license agreement with Immunomic Therapeutics
Thursday, 8 Oct 2015 07:30pm EDT 

Astellas Pharma Inc:Announces an exclusive worldwide license agreement with Immunomic Therapeutics, Inc. on Oct. 9, to the LAMP-vax products for the treatment or prevention of any and all allergic diseases in humans.According to the agreement, Immunomic Therapeutics will receive an upfront payment of $300 million and be entitled to receive 10% royalties of net sales of the potential products.  Full Article

Astellas Pharma announces license and collaboration agreement with Chromocell
Wednesday, 30 Sep 2015 01:00am EDT 

Astellas Pharma Inc:Entered into a license and collaboration agreement with Chromocell Corporation on Sep. 30, for the development and commercialization of therapeutics to treat neuropathic and other pain conditions.  Full Article

R&I affirms Astellas Pharma Inc's rating at "AA" and announces stable outlook
Thursday, 20 Aug 2015 02:00am EDT 

Astellas Pharma Inc:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA".Rating outlook stable.  Full Article

Astellas Pharma announces joint research alliance with Anokion SA
Tuesday, 2 Jun 2015 03:00am EDT 

Astellas Pharma Inc:Announces joint research alliance of type 1 diabetes, celiac disease treatment drug discovery with antigen-specific immune tolerance induction technology with Anokion SA on May 29.  Full Article

Astellas Pharma to retire treasury shares
Sunday, 10 May 2015 11:00pm EDT 

Astellas Pharma Inc:To retire 38 mln shares (1.68 pct stake) of its common stock on May 29.Says the total shares outstanding will be 2,221,823,175 shares after the retirement.  Full Article

BRIEF-Xcelra enters into drug collaboration with Astellas Pharma

* Xcelra enters into a drug repurposing collaboration with Astellas Pharma